Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
choriogonadotropin alfa
- Development stage
- Approved
- Lead developer
- Merck KGaA
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Choriogonadotropin alfa (recombinant human chorionic gonadotropin, r-hCG) is a recombinant glycoprotein hormone developed by Merck KGaA (marketed as Ovitrelle and Ovidrel). It is produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. Choriogonadotropin alfa acts as an analog of luteinizing hormone (LH) by binding to the LH/hCG receptor (LHCGR) on ovarian theca and granulosa cells. This binding triggers final follicular maturation, resumption of oocyte meiosis, and ovulation, mimicking the natural mid-cycle LH surge. It is indicated for the induction of final follicular maturation and early luteinization in women undergoing assisted reproductive technologies (ART), such as in vitro fertilization (IVF), as well as for the induction of ovulation and pregnancy in anovulatory or oligo-ovulatory infertile patients.
- Brand names
- OvidrelOvitrelle
- Other names
- choriogonadotropin alphachoriogonadotropine alfachoriongonadotropin alfachorionic gonadotrophin alfar-hCGrecombinant human chorionic gonadotropinrecombinant human chorionic gonadotrophinrhCG
02
Targets
LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on choriogonadotropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on choriogonadotropin alfa.